Acuity: "Acuity Pharmaceuticals is a product-focused ophthalmic pharmaceutical company leveraging its strong technology portfolio in RNA interference. Acuity is focusing on developing treatments for age-related macular degeneration (AMD) and diabetic retinopathy (DR), two of the leading causes of vision loss in the developed world.

Ophthalmic therapeutics represent an ideal market with favorable development dynamics for an early stage company. The ophthalmic market is rapidly growing and is underserved both domestically and internationally.

Acuity's initial priority is to commercialize the company's core technology by developing a therapeutic product to arrest and potentially reverse vision loss resulting from AMD and DR. Our lead compound, Cand5, is a proprietary RNAi-based pharmaceutical compound which has been shown to arrest VEGF production central to neovascularization in AMD. Cand5 substantially retards the growth of unwanted new blood vessels that lead to blindness in AMD and DR.

Additional ophthalmic conditions that can be treated with the same compound, perhaps with different formulations or administration, are also being explored. "

comments: RNAi therapeutics company -